Hepion Pharmaceuticals IncNASDAQ:HEPA
- LAST PRICE2.1118
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 2.1118
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HEPA |
|---|---|---|
| 09:52 ET | 9735 | 2.15 |
| 10:14 ET | 1342 | 2.18 |
| 10:53 ET | 656 | 2.12 |
| 11:54 ET | 608 | 2.13 |
| 11:56 ET | 700 | 2.17 |
| 12:07 ET | 100 | 2.16 |
| 12:34 ET | 2000 | 2.1589 |
| 12:48 ET | 200 | 2.135 |
| 01:10 ET | 100 | 2.14 |
| 01:35 ET | 300 | 2.13 |
| 01:51 ET | 100 | 2.16 |
| 01:57 ET | 100 | 2.17 |
| 02:13 ET | 100 | 2.2 |
| 02:45 ET | 462 | 2.16 |
| 02:58 ET | 100 | 2.2 |
| 03:18 ET | 100 | 2.195 |
| 03:20 ET | 3545 | 2.1124 |
| 03:25 ET | 3800 | 2.1761 |
| 03:27 ET | 3800 | 2.1139 |
| 03:41 ET | 700 | 2.18 |
| 03:48 ET | 1684 | 2.05 |
| 03:57 ET | 100 | 2.085 |
| 03:59 ET | 355 | 2.1118 |
Yesterday
DJ Hepion Pharma Shares Plunge 31% After Disclosing Plans to Wind Down Trial, from 6 hours ago by Dow Jones
6 hours ago by Dow JonesDJ Hepion Pharma to Wind-Down Phase 2b Ascend-NASH Trial, Cites Resource Constraints, from 7 hours ago by Dow Jones
7 hours ago by Dow JonesHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trial, from 8 hours ago by Dow Jones
8 hours ago by Dow JonesHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trial, from 8 hours ago by Dow Jones
8 hours ago by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Hepion Pharmaceuticals Inc | 11.6M | -0.2x | --- |
Connect Biopharma Holdings Ltd | 83.7M | 0.0x | --- |
Inhibitor Therapeutics Inc | 11.8M | -3.9x | --- |
Monopar Therapeutics Inc | 11.8M | -1.1x | --- |
Eterna Therapeutics Inc | 11.6M | -0.5x | --- |
Aslan Pharmaceuticals Ltd | 12.2M | -0.2x | --- |
Company Information
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation, and the treatment hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis and other liver diseases. The Company's cyclophilin inhibitor, rencofilstat is developed to offer benefits to address multiple complex pathologies relate to advanced liver disease. The Company’s rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. The Company provides an artificial intelligence (AI) tool, AI-POWR, that allows the selection of novel drug targets, biomarkers, and appropriate patient populations. The components of AI-POWR include access to publicly available databases, and in-house genomic and multi-omic big.
Contact Information
- Headquarters
- 399 Thornall StEDISON, NJ, United States 08837-2236
- Phone
- 732-902-4000
- Fax
- 732-902-4100
Executives
- Independent Chairman of the Board
- John Brancaccio
- Interim Chief Executive Officer
- John Cavan
- Director
- Michael Purcell
- Independent Director
- Timothy Block
- Independent Director
- Kaouthar Lbiati
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $11.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 5.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.63 |
EPS | $-12.41 |
Book Value | $1.51 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
